文献速递血液净化与透析

低白蛋白血症:为清除中分子尿毒症毒素值得付出的代价?

Hypoalbuminemia: a price worth paying for improved dialytic removal of middle-molecular-weight uremic toxins?
PubMed 文献 · Nephrol Dial Transplant · 2019-01-01

本文为综述,讨论血液透析滤过(HDF)与新型高通量透析膜在增加清除中分子尿毒症毒素的同时可增加白蛋白丢失。文中汇总指出终末期肾病低白蛋白血症成因众多,透析液丢失未必最重要;近期研究提示轻度低白蛋白血症本身并非透析患者死亡增加的独立预测因素,合并炎症时才提示预后不良。

要点

  • HDF与高通透性高通量膜均增加白蛋白丢失,需权衡清除中分子毒素的获益。
  • 终末期肾病低白蛋白血症原因多,透析液丢失未必是最主要因素。
  • 轻度低白蛋白血症合并炎症才提示不良预后,单纯低白蛋白未必独立预测死亡。

核心结论

  • 轻度低白蛋白血症本身可能不是透析患者死亡增加的独立预测因素,合并炎症时才是不良预后信号。
  • 低白蛋白血症是否成为增加中分子毒素清除的合理代价,可能取决于是否合并炎症。

研究设计与样本

  • 综述,总结近期关于透析液白蛋白丢失在低白蛋白血症中作用及合并炎症对结局影响的研究发现。

主要发现

  • HDF增加中分子尿毒症毒素清除,但需复杂设备并伴随大量置换液输注相关风险。
  • 新型高通量透析膜扩散通透性改善,无HDF上述限制,是具吸引力的替代方案。
  • 两种策略均增加透析液白蛋白丢失,引发对血清白蛋白下降的担忧。
  • 终末期肾病低白蛋白血症成因包括蛋白质能量消耗、炎症、容量扩张、肾脏丢失及透析液丢失,其中透析液丢失未必最重要。
  • 近期研究提示轻度低白蛋白血症本身并非透析患者死亡增加的独立预测因素,合并炎症时为不良预后征象。

临床怎么用

  • 评估透析患者低白蛋白血症时应同时排查炎症、蛋白质能量消耗、容量扩张等多种原因,而非仅归因于透析液丢失。
  • 选择HDF或高通量透析膜以增强中分子毒素清除时,需结合炎症状态权衡白蛋白丢失风险。

局限性

  • 本文为综述,未报告原始研究的具体样本量、数值与统计结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Hemodiafiltration (HDF) increases the removal of middle-molecular-weight uremic toxins and may improve outcomes in patients with end-stage kidney disease (ESKD), but it requires complex equipment and comes with risks associated with infusion of large volumes of substitution solution. New high-flux hemodialysis membranes with improved diffusive permeability profiles do not have these limitations and offer an attractive alternative to HDF. However, both strategies are associated with increased albumin loss into the dialysate, raising concerns about the potential for decreased serum albumin concentrations that have been associated with poor outcomes in ESKD. Many factors can contribute to hypoalbuminemia in ESKD, including protein energy wasting, inflammation, volume expansion, renal loss and loss into the dialysate; of these factors, loss into the dialysate is not necessarily the most important. Furthermore, recent studies suggest that mild hypoalbuminemia per se is not an independent predictor of increased mortality in dialysis patients, but in combination with inflammation it is a poor prognostic sign. Thus, whether hypoalbuminemia predisposes to increased morbidity and mortality may depend on the presence or absence of inflammation. In this review we summarize recent findings on the role of dialysate losses in hypoalbuminemia and the importance of concomitant inflammation on outcomes in patients with ESKD. Based on these findings, we discuss whether hypoalbuminemia may be a price worth paying for increased dialytic removal of middle-molecular-weight uremic toxins.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Ward RA, Beck W, Bernardo AA, et al. Hypoalbuminemia: a price worth paying for improved dialytic removal of middle-molecular-weight uremic toxins? Nephrol Dial Transplant. 2019. PMID: 30102329. doi:10.1093/ndt/gfy236

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。